Sutro Biopharma, Inc. (S09.F)
- Zacks
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
AnaptysBio (ANAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
- GlobeNewswire
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in follow up – SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today
- Simply Wall St.
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by...
